Cardiol Therapeutics Inc. (CRDL)
NCM · Healthcare · Drug Manufacturers - Specialty & Generic
Closing price as of 2026-06-12 · Source: TEK2day Finance
Key Metrics
About Cardiol Therapeutics Inc.
Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product candidate is CardiolRx, which is in Phase III multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis. The company is also developing CRD-38, a novel subcutaneously administered drug formulation of cannabidiol for the treatment of heart failure. Cardiol Therapeutics Inc. was incorporated in 2017 and is headquartered in Oakville, Canada.
Quarterly Financials
| Metric | 2025-06-30 | 2025-09-30 | 2025-12-31 | 2026-03-31 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | -7.7M | -10.2M | -8.0M | -9.7M |
| Net Income | -8.4M | -10.0M | -7.2M | -10.8M |
| Diluted EPS | $-0.10 | $-0.12 | $nan | $-0.10 |
Annual Financials
| Metric | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | -41.3M | -29.8M | -40.3M | -34.3M |
| Net Income | -30.9M | -28.1M | -36.7M | -33.8M |
| Diluted EPS | $-0.49 | $-0.44 | $-0.51 | $-0.39 |